ArticleThe American journal of pathology2010
Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Pancreatic Neuroendocrine Tumor: The Case Report of a Patient with GermlineJournal of clinical medicine · 2024Article
- FANCD2 as a ferroptosis-related target for recurrent implantation failure by integrated bioinformatics and Mendelian randomization analysis.Journal of cellular and molecular medicine · 2024Article
- Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer.World journal of clinical oncology · 2024Article
- FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.European journal of medical research · 2023Article
- Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells.Biomolecules · 2023Article
- Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma.Oncogenesis · 2021Article
- FANCD2 Confers a Malignant Phenotype in Esophageal Squamous Cell Carcinoma by Regulating Cell Cycle Progression.Cancers · 2020Article
- Subcellular localization of FANCD2 is associated with survival in ovarian carcinoma.Oncotarget · 2020Article
- Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.Frontiers in cell and developmental biology · 2020Review
- Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of theArchives of medical science : AMS · 2019Article
- Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.Oncology letters · 2019Article
- Expression of FANCD2 is associated with prognosis in patients with nasopharyngeal carcinoma.International journal of clinical and experimental pathology · 2019Article
- S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.Cancer research · 2017Article
- Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response.British journal of cancer · 2016Article
- Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.The Journal of investigative dermatology · 2015Article
- RECQL5 and BLM exhibit divergent functions in cells defective for the Fanconi anemia pathway.Nucleic acids research · 2015Article
- Article
- Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia.Oncogene · 2013Article
- Article
- Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
FANCD2, a pivotal protein in the Fanconi anemia and BRCA pathway/network, is monoubiquitylated in the nucleus in response to DNA damage. This study examines the subcellular location and relationship with prognostic factors and patient survival of FANCD2 in breast cancer. Antibodies to FANCD2 were used to immunocytochemically stain 16 benign and 20 malignant breast specimens as well as 314 primary breast carcinomas to assess its association with subcellular compartment and prognostic factors using Fisher's Exact test or with patient survival over 20 years using Wilcoxon-Gehan statistics. Immunoreactive FANCD2 was found in the nucleus and cytoplasm of all 16 benign tissues, but nuclear staining was lost from a significant 19/20 malignant carcinomas (P < 0.0001). Antibodies to FANCD2 stained the cytoplasm of 196 primary carcinomas, leaving 118 as negatively stained. Negative cytoplasmic staining was significantly associated with positive staining for the metastasis-inducing proteins S100A4, S100P, osteopontin, and AGR2 (P < or = 0.002). Survival of patients with FANCD2-negative carcinomas was significantly worse (P < 0.0001) than those with positively stained carcinomas, and only 4% were alive at the census date. Multivariate regression analysis identified negative staining for cytoplasmic FANCD2 as the most significant indicator of patient death (P = 0.001). Thus FANCD2's cytoplasmic loss in the primary carcinomas may allow the selection of cells overexpressing proteins that can induce metastases before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.